Cannabinoid, Urine
The Urine Cannabinoid test is designed to detect the presence of the class of drugs termed cannabinoids in human urine. The active agent in marijuana is generally considered to be ∆9 - tetrahydrocannabinol (THC). THC is rapidly absorbed and almost completely metabolized, whether inhaled or absorbed in the gastrointestinal tract and excreted into the urine. The acute effects of marijuana use, concomitant with the desired “high,” are memory impairment, time confusion, interference with learning, impaired motor skills and depersonalization. These effects are also manifested in chronic users in addition to cardiovascular, pulmonary, and reproductive effects. In the early 1990s the receptors for THC were discovered and labeled CB1 and CB2. The CB1 receptors are found mostly in the brain predominantly in the frontal cortex, basal ganglion and cerebellum, striatum and hippocampus. These areas are consistent with the clinical effects on higher cerebral functioning, physical motion including coordination, reward and memory respectively. CB2 receptors are located external to the brain in T and B lymphycytes, macrophages in the spleen, peripheral nerves and vas deferens. These receptors inhibit the release of several neurotransmitters including gamma-aminobutyric acid, dopamine, serotonin, norepinephrine, acetylcholine and glutamate.
Marijuana is usually smoked, but may be ingested, either incorporated into food or as a liquid extract (tea). It is rapidly absorbed from the lungs into the blood with rapid onset of effects (minutes); the onset is slower (1 to 2 hours) but prolonged when ingested. THC is metabolized to several metabolites, one being ∆9 - tetrahydrocannabinol carboxylic acid (THC-COOH). This is the metabolite most frequently used in this assay. The natural cannabinoids and their metabolic products are fat soluble and are stored in the body’s fatty tissues, including brain tissue, for prolonged periods after use. THC has some medicinal purposes such as stimulation of hunger in those undergoing chemotherapy or afflicted with anorexia and the treatment of glaucoma. It is most commonly used, however, for it's side effects including feelings of euphoria, alteraltion of sense of time and distance, increased sensory experiences, relaxation and feeling of detachment. Unpleasant side effects are not uncommon and include anxiety, panic, deleriumand unpleasant somatic sensations. Other deleterious effects include short term memory impairment, impairment of pulmonary macrophage function, tachycardia with increased cardiac output, angina, postural hypotension and advese cardiovascular events in those with a history of coronary artery disease (myocardial infarction, stroke). Acute toxicity in the average adult is not life threatening and manifests as impaired speech, postural hypotension, impaired coordination and difficulty concentrating. In children the consequences are more severe and can include apnea, bradycardia, cyanosis and obtundtion. Approximately 7 to 10 percent of recreational users become psychologically dependent upon THC through the dopaminergic neurons of the ventral tegmental area of the brain which mediate the reinforcing rewarding drive system. Although there have been no deaths due to direct THC toxicity and long term use has not been shown to result in increased incidence of diseases such as coronary artery disease or cancer, driving after smoking even small amounts doubles the rate of fatal automobile accidents.
Cannabinoid metabolites are found in blood, bile, feces, and urine and may be detected in urine within hours of exposure. Because of their fat solubility, they also remain in the body’s fatty tissues with slow release and subsequent urinary excretion for days, weeks, and even months after the last exposure, depending on the intensity and frequency of use.
This test is designed to detect the presence of the class of drugs termed cannabinoids in human urine as a qualitative or semi-quantitative screening test. Different cut-off values are established for the positivity of THC, which are determined by the type of specimen submitted for analysis, such as pre-employment, employment, or department of transportation.
- Therapeutic drug monitoring
- Drug abuse evaluation
- Toxicity assessment
Negative (less than cutoff)
Cut-Off Ranges: Cut-Off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular manufacturer of the assay, but are frequently in the range of < 20 ng/mL.
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 5 days
- Refrigeration: 7 days
- J Psychosom Res. 2010 Dec;69(6):533-9. [PMID: 21109040]
- Mandatory Guidelines for Federal Workplace Drug Testing Program. National
- Institute on Drug Abuse. Federal Register Vol. 53, No. 69, p 11979 (1988).
- Urine Testing for Drug Abuse. National Institute on Drug Abuse (NIDA) Research Monograph. 73, 1986.